Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in...

Area of Science:

• Immunology
• Neuroimmunology
• Pharmacology

Background:

• Dendritic cells (DCs), including myeloid (mDCs) and plasmacytoid (pDCs) subsets, play critical roles in initiating and regulating immune responses in multiple sclerosis (MS).
• Natalizumab (NTZ) is an approved therapy for MS that targets very late antigen-4 (VLA-4) integrins on leukocytes.

Purpose of the Study:

• To investigate the effect of Natalizumab (NTZ) treatment on circulating dendritic cell (DC) subsets and VLA-4 expression in relapsing-remitting MS patients.
• To analyze the in vitro impact of NTZ on VLA-4 expression and T-cell stimulation in both MS patients and healthy controls.

Main Methods:

• Analysis of circulating DC subsets and VLA-4 expression in 6 relapsing-remitting MS patients before and after 1 year of NTZ treatment.
• In vitro coculture experiments with peripheral blood mononuclear cells and pDCs from MS patients and healthy controls using varying NTZ doses.

Main Results:

• Significant decrease in VLA-4 expression levels on both pDCs and mDCs in MS patients during NTZ treatment.
• Dose-dependent down-regulation of VLA-4 expression on DCs observed in both MS patients and healthy controls in vitro.
• Reduced capacity of DCs to stimulate antigen-specific T-lymphocyte responses in the presence of NTZ.

Conclusions:

• NTZ treatment effectively reduces VLA-4 expression on circulating DCs in MS patients.
• The therapeutic effects of NTZ may involve inhibiting DC transmigration into the central nervous system and impairing DC-T cell interactions.
• NTZ demonstrates a dose-dependent effect on DC function and VLA-4 expression in both healthy and MS individuals.